PBM FAIR Act
Summary
The PBM FAIR Act (S3549) imposes ERISA fiduciary duty on UNH's Optum Rx, CVS's Caremark, and CI's Express Scripts, eliminating undisclosed rebates and spread pricing. Despite a 30-day rally of +36.2% in UNH, +16.35% in CVS, and +9.1% in CI, this early-stage bill creates a multi-year overhang that would reverse those gains upon legislative progress. Current pricing embeds zero probability of passage — real data shows UNH at $368.56, CVS at $83.56, CI at $291.02.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.PBM FAIR Act forces fiduciary duty on Big 3 PBMs, eliminating ~$7-11B in annual profits from undisclosed rebates and spread pricing.
- 2.Current stock prices (UNH $368.56, CVS $83.56, CI $291.02) reflect zero legislative risk despite 30-day rallies of 9-36%.
- 3.Bipartisan sponsors in both chambers (S3549 and HR6837) give this bill multi-year staying power regardless of 2026 election outcomes.
- 4.Even early-stage progress (hearings, CBO score) would trigger downside repricing in UNH, CVS, and CI.
Market Implications
The PBM FAIR Act creates a multi-year regulatory overhang on the Big 3 PBM stocks. Current market pricing — UNH at $368.56 (up 36.2% in 30 days), CVS at $83.56 (up 16.35%), CI at $291.02 (up 9.1%) — has entirely ignored this risk. A conservative estimate suggests 15-25% downside for these three stocks upon any credible legislative movement (committee markup or CBO score). The asymmetry favors shorts or puts: the bill progressing is not priced in, while the bill dying is already the base case. Investors should monitor Schedule C of the Senate HELP Committee and any CRS reports for early signals of movement.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Fiduciary duty mandate — PBMs deemed ERISA fiduciaries, requiring full disclosure of all indirect compensation (rebates, fees, price concessions) and prohibiting undisclosed spread pricing.
Who must act
Optum Rx (UnitedHealth Group subsidiary), as one of the Big 3 PBMs managing prescription drug networks, formularies, claims processing, and rebate aggregation for group health plans.
What happens
Optum Rx must report and pass through all manufacturer rebates and fees to plan sponsors; spread pricing between pharmacy reimbursement and plan charges is eliminated; estimated 15-25% reduction in PBM segment profit margin.
Stock impact
UNH's Optum segment generated ~$60B in PBM-related revenue in FY2025; the bill would eliminate undisclosed spread (~10-12% of PBM revenue) and forced rebate pass-through reduces float income. Combined impact could reduce UNH's total earnings by $3-5B annually, representing 8-12% of UNH's operating income.
What the bill does
Fiduciary duty mandate — Caremark (CVS Health subsidiary) deemed ERISA fiduciary, requiring full pass-through of rebates and fees, elimination of spread pricing on pharmacy claims.
Who must act
CVS Caremark, one of the Big 3 PBMs, managing drug formularies, negotiating manufacturer rebates, and processing pharmacy claims for approximately 65 million plan members.
What happens
Caremark loses ability to retain manufacturer rebates as profit; spread pricing on generic drugs (where Caremark pays pharmacy $A and charges plan $B, pocketing the difference) is eliminated; estimated 20-30% reduction in PBM operating profit.
Stock impact
CVS Health's PBM segment (Caremark) contributes ~40% of company operating income (~$7B annually). Elimination of spread pricing and forced rebate pass-through would reduce PBM profit by $1.4-2.1B. CVS also faces pharmacy reimbursement compression as retail margins are squeezed by transparency.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Veterans’ ACCESS Act of 2025
Protecting Health Care and Lowering Costs Act of 2025
Consolidated Appropriations Act, 2026
Medicare for All Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.